The DigiCare-ASCVD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated whether digital remote management is superior to usual care in reducing risk of atherosclerotic cardiovascular diseases and improving blood pressure control, glycemic control, lipids control, medication compliance and lifestyle.
10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model
Adultd aged ≥ 35 years
Able to use a smartphone (or assisted by family) and agrees to remote management
Signed informed consent
History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery
Moderate to severe hepatic dysfunction (Child-Pugh class B-C)
CKD stages 4-5 (eGFR <30 ml/min/1.73m²) or on dialysis
Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient
Beijing Anzhen Hospital
Lead sponsor